MS-553 shows promise in treating chronic lymphocytic leukaemia
MS-553 shows promise in treating chronic lymphocytic leukaemia
Enhancing cancer care in Africa: Patient perspectives and quality improvement
Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety
TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML
Consolidation treatment delays do not compromise survival in MRD-negative adult ALL
Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC
Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer
Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL
Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL
Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer
Sacituzumab govitecan improves quality of life in untreated advanced TNBC
Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab